Cholestan-3-One

Cholestan-3-One

SCHEMBL643015

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 4/20 0.74
SRD5A1 P18405 4/20 0.66
SRD5A2 P31213 3/20 0.66
CYP2D6 P10635 1/20 0.65
CYP2C19 P33261 1/20 0.65
INPP5D Q92835 1/20 0.64
NR3C1 P04150 1/20 0.61
SHBG P04278 1/20 0.61
PGR P06401 1/20 0.61
SERPINA6 P08185 1/20 0.61
NR3C2 P08235 1/20 0.61
CYP3A4 P08684 1/20 0.61
AR P10275 1/20 0.61
CYP19A1 P11511 1/20 0.61
HSD17B10 Q99714 1/20 0.61
MGAM O43451 1/20 0.61
USP2 O75604 2/20 0.59
CDC25A P30304 2/20 0.58
POLA1 P09884 1/20 0.58
FGF2 P09038 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cholestan-3-One SCHEMBL31415973 1.00 GPBAR1 (0.74) GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19
Cholestan-3-One SCHEMBL14078297 1.00 GPBAR1 (0.74) GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19
Cholestan-3-One SCHEMBL3034745 1.00 GPBAR1 (0.74) GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19
Cholestan-3-One SCHEMBL17817037 1.00 GPBAR1 (0.74) GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19
Cholestan-3-One SCHEMBL17817346 1.00 GPBAR1 (0.74) GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19
Cholestan-3-One SCHEMBL14313461 1.00 GPBAR1 (0.74) GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19
Cholestan-3-One SCHEMBL24151938 1.00 GPBAR1 (0.74) GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19
Cholestan-3-One SCHEMBL14360529 1.00 GPBAR1 (0.74) GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19
Cholestan-3-One SCHEMBL12273856 1.00 GPBAR1 (0.74) GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19
Cholestan-3-One SCHEMBL30428888 1.00 GPBAR1 (0.74) GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077000-A1 METABOLIC MODULATION OF INTRATUMORAL CHOLESTEROL WITH ENGINEERED BACTERIA FOR THE TREATMENT OF CANCERS UNIV HONG KONG BAPTIST UNIV (CN) 2026-03-19 US claimed
WO-2024259158-A2 LIPID NANOPARTICLES FOR PEPTIDE DELIVERY AND METHODS OF MAKING AND USING THE SAME CORNELL UNIVERSITY (US) 2024-12-19 WO claimed
US-12138285-B2 Cholesterol reducing compositions and methods of use thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-11-12 US claimed
US-20240024381-A1 CHOLESTEROL REDUCING COMPOSITIONS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-01-25 US claimed
US-11633436-B2 Cholesterol reducing compositions and methods of use thereof THE BROAD INSTITUTE, INC. (US) 2023-04-25 US claimed
US-20210128642-A1 CHOLESTEROL REDUCING COMPOSITIONS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-05-06 US claimed
EP-3781697-A1 METHOD FOR DETERMINING CHEMICAL COMPOUNDS IN WASTE Renescience A/S (DK) 2021-02-24 EP claimed
WO-2019201765-A1 METHOD FOR DETERMINING CHEMICAL COMPOUNDS IN WASTE RENESCIENCE A/S (DK) 2019-10-24 WO claimed
EP-2850430-A1 ANALYSIS OF A PANEL OF CEREBROTENDINOUS XANTHOMATOSIS BIOMARKERS USING SITE SPECIFIC DERIVATION AND LC/MS/MS WORKFLOW Dh Technologies Development Pte. Ltd. (SG) 2015-03-25 EP claimed
EP-2747750-A2 LIPOSOME COMPRISING AT LEAST A CHOLESTEROL DERIVATIVE Trophos (FR) 2014-07-02 EP claimed
EP-1601363-A2 USE OF DERIVATIVES OF CHOLEST-4-EN-3-ONE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, NOVEL DERIVATIVES AND PREPARATION METHOD THEREOF Trophos (FR) 2005-12-07 EP claimed
WO-2004082581-A2 USE OF DERIVATIVES OF CHOLEST-4-EN-3-ONE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, NOVEL DERIVATIVES AND PREPARATION METHOD THEREOF TROPHOS (FR) 2004-09-30 WO claimed
US-6312919-B1 CONVERTING CHOLESTEROL TO 4-CHOLESTEN-3-ONE, THEN TO COPROSTAN-3-ONE, AND THEN TO COPROSTANOL BY VARIOUS DEHYDROGENASES ISOLATED FROM A EUBACTERIUM SPECIES; FOR REDUCED CHOLESTEROL FOODS AND FEEDS KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-11-06 US claimed
US-20010034041-A1 Process for producing a cholesterol-reduced substance SAITOH CHIAKI (JP) 2001-10-25 US claimed
US-20010005587-A1 Cholesterol dehydrogenase, coprostan-3-one dehydrogenase and 4-cholesten-3-one dehydrogenase, compositions containing the dehydrogenases, and method for reducing amount of cholesterol using the compositions SAITOH CHIAKI (JP) 2001-06-28 US claimed
EP-0879892-A1 PROCESS FOR PREPARING CHOLESTEROL-LOWERING COMPOUND Kyowa Hakko Co., Ltd. (JP) 1998-11-25 EP claimed
EP-0465155-B1 Non-linear optical material containing steroidal ketone compound HITACHI CHEMICAL CO LTD (JP) 1996-02-28 EP claimed
US-4438033-A Steroidal chiral phosphines, methods for their preparation, catalytic systems containing them and catalytic processes in which they are used CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1984-03-20 US claimed
EP-0081149-A1 New steroidal chiral phosphines, methods for their preparation, catalytic systems containing them and catalytic processes in which they are used CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1983-06-15 EP claimed
US-4020059-A Process for preparing tertiary amines NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JA) 1977-04-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024381-A1 CHOLESTEROL REDUCING COMPOSITIONS AND METHODS OF USE THEREOF CETP, DHCR7, HMGCR GPBAR1 1197/4885SRD5A1 222/4885SRD5A2 269/4885
US-11633436-B2 Cholesterol reducing compositions and methods of use thereof CETP, DHCR7, HMGCR GPBAR1 1197/4885SRD5A1 222/4885SRD5A2 269/4885
US-12138285-B2 Cholesterol reducing compositions and methods of use thereof CETP, DHCR7, HMGCR GPBAR1 1197/4885SRD5A1 222/4885SRD5A2 269/4885
US-20260077000-A1 METABOLIC MODULATION OF INTRATUMORAL CHOLESTEROL WITH ENGINEERED BACTERIA FOR THE TREATMENT OF CANCERS CYP4X1, CYP46A1, CYP11A1 GPBAR1 473/4885SRD5A1 42/4885SRD5A2 41/4885
US-20210128642-A1 CHOLESTEROL REDUCING COMPOSITIONS AND METHODS OF USE THEREOF CETP, DHCR7, HMGCR GPBAR1 1197/4885SRD5A1 222/4885SRD5A2 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.